Skip to content

Aurelija Ippolito

3 papers in the library · 18 citations · publishing 2024-2025

Papers

Sort Most recent Most cited

Evidence that 5-HT2A receptor signalling efficacy and not biased agonism differentiates serotonergic psychedelic from non-psychedelic drugs.

British Journal of Pharmacology June 22, 2025 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 9 citations

Serotonergic psychedelic drugs are under investigation as therapies for various psychiatric disorders, including major depression. Although serotonergic psychedelic drugs are 5-HT2A receptor agonists, some such agonists are not psychedelic, potentially due to differences in 5-HT2A receptor ligand bias or signalling efficacy. Here, we investigated 5-HT2A receptor signalling properties of...

Neuropsychopharmacology of hallucinogenic and non-hallucinogenic 5-HT2A receptor agonists.

British Journal of Pharmacology May 23, 2025 Trevor Sharp, Aurelija Ippolito 8 citations

Psychedelic drugs such as LSD and psilocin were once relegated to the fringes of medical research because of their association with counterculture movements and a perceived concern about harm through recreational use, and their consequent legal prohibition in the early 1970s. However, these drugs are now experiencing a renaissance in the field of psychiatry based on increasing evidence that...

Increased 5-HT 2A receptor signalling efficacy differentiates serotonergic psychedelics from non-psychedelics

bioRxiv (Cold Spring Harbor Laboratory) June 16, 2024 Aurelija Ippolito, Sridhar Vasudevan, Shaun Hurley et al. 1 citation preprint

ABSTRACT Background and Purpose Serotonergic psychedelic drugs are under renewed investigation for the potential treatment of several psychiatric disorders. While all serotonergic psychedelics have 5-HT 2A receptor activity, the explanation for why some 5-HT 2A receptor agonists are not psychedelic is unknown. To address this question, we investigated the 5-HT 2A receptor signalling bias and...